HOME >> MEDICINE >> NEWS
Scent prediction

This release is also available in German.

The scent of lily of the valley hangs in the air for readers of the journal Angewandte Chemie: just rub the journal's cover and enjoy a lily-of-the-valley scent. Lily-of-the-valley scent components can also be found within the pages of the journal: an interdisciplinary team headed by Reinhold Tacke (Inorganic Chemistry, University of Wrzburg), Philip Kraft (Scent Research, Givaudan Schweiz Inc.), and Hanns Hatt (Cell Biology, University of Bochum) have attempted a "scent prediction" to test their computer model of lily-of-the-valley fragrance receptor hOR17-4. This molecule was characterized in detail as the first human scent receptor by Hatt and his co-workers, who also discovered it in sperm.

A fragrance is usually composed of a mixture of many different scented substances. Each of these individual substances can react with several of the approximately 347 scent receptors in our nose and show a complex scent. "When developing new fragrances, we have to rely on correlations between structure and effect derived from model substances as well as intuition," says Kraft. With the help of sperm, however, it is possible to study the lily-of-the-valley receptor in virtual isolation and simulate the primary process of scent sensing by computer.

An olfactory receptor responds to a scent molecule when it fits into the receptor's binding cavity. If the structure of the cavity is known, it should be possible to use computer models to predict whether a scent activates the receptor in question and to what degree. To prove this theory, the scientists investigated how the replacement of one carbon atom with a silicon atom affects the scent of lily-of-the-valley fragrance components lilial and bourgeonal, and whether this subtle alteration, which has minimal influence on the molecular shape, can also be predicted quantitatively. The
'"/>

Contact: Reinhold Tacke
r.tacke@mail.uni-wuerzburg.de
49-931-888-5250
John Wiley & Sons, Inc.
18-Apr-2007


Page: 1 2

Related medicine news :

1. Scent of fear impacts cognitive performance
2. Newer biomarkers add small improvement in cardiovascular risk prediction to established risk factors
3. Genomic tests improve prediction of breast cancer response to chemotherapy, hormonal therapy
4. Hopkins researchers identify risk factors for prediction of lethal prostate cancer after recurrence

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Scent prediction

(Date:7/31/2015)... ... ... ZH Healthcare announces a new cloud based service delivering Health IT as ... Service (HITaaS) is a Healthcare dedicated cloud based service that sits over infrastructure as ... all aspects of infrastructure, security, runtime, middleware, OS, virtualization, Servers, storage, contracts, and ...
(Date:7/31/2015)... ... ... therapy for knee osteoarthritis is an important part of knee pain treatment. ... doing what they want or need to do. The patient may have trouble getting in ... exercise regime may be limited by the pain in their knee. When a patient sees ...
(Date:7/31/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... from 9am – 12pm. Timber frame raisings are special, celebrating both craft ... the culmination of months of effort, planning, fundraising, and dreaming takes shape. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... The Radiology ... Michael Burgess, MD, (R-Tex) presenting “What’s Next for Health Care: A View From Capitol ... and founder of the Congressional Health Caucus, Rep. Burgess has a special understanding of ...
(Date:7/31/2015)... ... ... “ Crack’em ” was featured on NewsWatch as part of its monthly ... Forstrom, a technology expert and special reporter for NewsWatch, conducted the review and shared ... can be a very messy experience, especially when cracking eggs. Cracking an egg is ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Make Less Mess while Cooking with Crack’em 2
(Date:7/30/2015)... , July 30, 2015 Eisai Inc. announced ... the United States , European Union and ... and MHLW, respectively) for eribulin, for the treatment of ... received prior chemotherapy for advanced or metastatic disease. ... from a pivotal global Phase 3 clinical trial (Study ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
(Date:7/30/2015)... FRANCISCO , July 30, 2015 ... market is expected to reach USD 23.01 million ... View Research, Inc. Growing base of geriatric population, increasing ... infections, and rising level of awareness among target customer ... rendering drivers over the forecast period. According to estimates ...
Breaking Medicine Technology:Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 2ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 3ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 4ENT Devices Market Size to Reach $23.01 Billion by 2022: Grand View Research, Inc. 5
Cached News: